About one year ago Illumina agreed to splash out $1.2 billion on Pacific Biosciences, a rival maker of DNA sequencing technology. Now the Federal Trade Commission is looking to block the deal, and says it was meant to steamroll a competitor and maintain Illumina’s “monopolist” position atop the industry.
The San Diego-based genomics giant (NASDAQ: ILMN) dominates the market when it comes to technology for sequencing, or “reading,” the genetic code. Illumina machines read short pieces of DNA that have been chopped up, copied, then reassembled. PacBio (NASDAQ: PACB) is an attractive acquisition target because of its prowess with... Read more »
UNDERWRITERS AND PARTNERS
